Pepsi has launched a new beverage platform called "House of Treats" to compete with Coca-Cola's Freestyle. Unlike Freestyle, which allows customers to create their own drinks, Pepsi's platform focuses on offering a curated menu of experimental and elevated flavors like Yuzu Lychee and White Peach Sangria. The "House of Treats" is initially rolling out in the UK and select European markets, with a US launch still unconfirmed.

The J.M. Smucker Co. is seeing stabilization and a brighter path for its Sweet Baked Snacks business, following struggles after the 2023 acquisition of Hostess Brands. Management is guiding for a 30% rise in profitability for this segment in fiscal 2027 compared to fiscal 2026, focusing on cost control, trade execution, and price increases for certain products. Despite a sales decline in fiscal 2026, the company is prioritizing stabilization and improved profitability, with the expectation of future top-line growth.

Merck Animal Health is set to acquire TARGAN, an agricultural technology company specializing in automated biodevice solutions for the poultry industry. This acquisition will expand Merck Animal Health's presence in poultry production technology, strengthen its animal health innovation platform, and integrate TARGAN's automated hatchery technologies, such as WingScan™ for chick sorting and a high-speed precision ocular spray for vaccine delivery. The deal aims to enhance efficiency, animal welfare, and vaccine administration in commercial poultry operations.

AT&T's stock saw a notable rise as investors focused on the company's reiterated outlook, particularly its fiber growth strategy and capital return plans. Management reaffirmed its full-year 2026 financial outlook and a Q2 free cash flow forecast of $4.0 billion to $4.5 billion, which will be used for dividends, buybacks, and debt reduction. The company is heavily investing in its fiber network, aiming to reach over 40 million locations by year-end 2026, and is also targeting over $45 billion in shareholder returns between 2026 and 2028.

General Electric Company (GE) has announced the appointment of Judson Althoff to its Board of Directors, effective June 24, 2026. Althoff, currently the CEO of Microsoft's Commercial Business, will serve as an independent director, increasing the board's size. His extensive experience in driving growth and commercial strategy at Microsoft is expected to be a valuable asset to GE.

The Rosen Law Firm is investigating potential securities claims against Barclays PLC (NYSE: BCS) for allegedly issuing misleading business information. This follows reports of Barclays' exposure to UK mortgage provider Market Financial Solutions Ltd (MFS), which experienced an "implosion," causing Barclays' American Depositary Shares (ADS) to decline. Investors who purchased Barclays securities are encouraged to contact the firm regarding a potential class action lawsuit.

China's export restrictions on indium phosphide (InP), a critical material for high-speed optical chips in AI data centers, are causing significant disruptions globally. Since February 2025, Chinese export licenses for InP have been throttled, leading to increased prices and supply chain bottlenecks for major photonics product makers like Coherent and Lumentum. The situation highlights InP's emergence as a strategic trade weapon for Beijing, pushing U.S. firms to seek alternative suppliers and increase domestic production, though capacity expansion is slow.

Honeywell International (HON) has seen its share price pull back recently, leading investors to reassess its value. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 16.9% at its current price of US$205.88. Additionally, its P/E ratio of 32.88x is below Simply Wall St's Fair Ratio of 35.59x, further indicating undervaluation.

Johnson & Johnson announced positive late-stage results for its therapy, IMAAVY (nipocalimab-aahu), in treating warm autoimmune hemolytic anemia, an orphan disease with no FDA-approved treatments, showing significant improvements in hemoglobin levels and patient outcomes. The drug's safety profile was consistent with its approved use for other conditions. Johnson & Johnson has already submitted a supplemental Biologics License Application for IMAAVY, which has been granted Priority Review status by the U.S. Food and Drug Administration.

Hewlett Packard Enterprise (NYSE:HPE) is set to trade ex-dividend in four days, with a payment of US$0.1425 per share. The company has a trailing dividend yield of 1.3% and its dividend payments are covered by both profits (50% payout ratio) and free cash flow (21% payout). However, HPE's earnings per share have declined by approximately 17% annually over the last five years, raising questions about the long-term sustainability of the dividend despite a historical 10.0% annual increase in payouts.